IOVA Iovance Biotherapeutics, Inc.
$8.70
Iovance Biotherapeutics, Inc. (IOVA) Earnings News
Earnings press releases, previews and reviews for Iovance Biotherapeutics, Inc. (IOVA), newest first. Our most recent is review: Iovance Beats With Record Quarter and 60% Gross Margin, but Reaffirmed Guide Implies a Flat Fourth Quarter.
Thursday
November 5, 2026
11:03 AM ET
Iovance Beats With Record Quarter and 60% Gross Margin, but Reaffirmed Guide Implies a Flat Fourth Quarter
Earnings Whispers · Review
Thursday
November 5, 2026
7:00 AM ET
Iovance Biotherapeutics Reports Record Third Quarter 2026 Revenue of ~$122M, Business Achievements, and Corporate Updates
Wednesday
October 28, 2026
7:00 PM ET
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Wednesday
October 28, 2026
2:33 PM ET
Iovance's Raised Outlook Implies a Bigger Third Quarter Than Wall Street Models
Earnings Whispers · Preview
Tuesday
October 27, 2026
7:00 AM ET
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
Tuesday
September 29, 2026
7:00 AM ET
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million
Thursday
August 6, 2026
7:01 AM ET
Iovance Biotherapeutics Reports Record Second Quarter 2026 Revenue of ~$99M, Business Achievements, and Corporate Updates
Thursday
July 30, 2026
8:00 AM ET
Iovance Biotherapeutics to Report Second Quarter 2026 Financial Results and Corporate Updates on Thursday, August 6, 2026